Your browser is no longer supported. Please, upgrade your browser.
Settings
NVS Novartis AG daily Stock Chart
NVS [NYSE]
Novartis AG
Index- P/E26.77 EPS (ttm)3.23 Insider Own9.30% Shs Outstand2.28B Perf Week1.66%
Market Cap210.08B Forward P/E13.71 EPS next Y6.31 Insider Trans0.00% Shs Float2.30B Perf Month3.66%
Income7.45B PEG3.80 EPS next Q1.42 Inst Own10.90% Short Float0.12% Perf Quarter3.40%
Sales49.93B P/S4.21 EPS this Y-43.60% Inst Trans-2.15% Short Ratio1.08 Perf Half Y-6.33%
Book/sh22.37 P/B3.86 EPS next Y10.69% ROA10.30% Target Price102.67 Perf Year-1.37%
Cash/sh2.05 P/C42.24 EPS next 5Y7.05% ROE23.10% 52W Range69.18 - 99.84 Perf YTD-8.69%
Dividend3.09 P/FCF35.49 EPS past 5Y-6.50% ROI8.60% 52W High-13.40% Beta0.54
Dividend %3.57% Quick Ratio0.50 Sales past 5Y-1.90% Gross Margin71.30% 52W Low24.98% ATR1.57
Employees109000 Current Ratio0.70 Sales Q/Q11.50% Oper. Margin19.20% RSI (14)55.15 Volatility1.75% 1.49%
OptionableYes Debt/Eq0.72 EPS Q/Q18.90% Profit Margin24.30% Rel Volume0.63 Prev Close86.68
ShortableYes LT Debt/Eq0.50 EarningsApr 28 BMO Payout53.50% Avg Volume2.63M Price86.46
Recom1.00 SMA201.45% SMA502.50% SMA200-2.30% Volume1,662,165 Change-0.25%
Mar-10-20Upgrade Morgan Stanley Underweight → Equal-Weight
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Jun-02-20 10:53AM  
09:00AM  
Jun-01-20 10:05AM  
May-31-20 05:32PM  
May-28-20 02:26PM  
11:42AM  
10:26AM  
09:40AM  
May-27-20 07:25AM  
03:59AM  
May-22-20 07:46AM  
May-19-20 10:52AM  
10:13AM  
08:24AM  
May-18-20 12:22PM  
May-16-20 12:00AM  
May-15-20 02:59AM  
May-14-20 11:51AM  
02:43AM  
May-12-20 05:45PM  
May-08-20 11:04AM  
May-07-20 07:41AM  
May-05-20 03:26PM  
May-04-20 05:59PM  
03:50PM  
03:25PM  
08:55AM  
May-01-20 07:54AM  
Apr-30-20 12:52PM  
Apr-29-20 11:00AM  
10:05AM  
01:56AM  
01:48AM  
Apr-28-20 04:07PM  
02:10PM  
10:32AM  
08:51AM  
03:36AM  
01:24AM  
Apr-27-20 01:05PM  
10:43AM  
Apr-24-20 02:22PM  
09:10AM  
06:35AM  
Apr-23-20 11:02AM  
Apr-22-20 07:51AM  
Apr-21-20 12:47PM  
12:31PM  
08:19AM  
Apr-20-20 05:43PM  
04:48PM  
02:56PM  
11:35AM  
09:49AM  
09:01AM  
08:41AM  
08:00AM  
05:57AM  
03:25AM  
02:25AM  
02:19AM  
Apr-19-20 09:03AM  
Apr-17-20 07:20PM  
04:49PM  
11:16AM  
Apr-16-20 11:39AM  
11:37AM  
Apr-15-20 09:32PM  
Apr-13-20 02:57PM  
Apr-07-20 04:51PM  
09:56AM  
Apr-06-20 12:12PM  
Apr-05-20 10:22AM  
Apr-03-20 10:55AM  
10:51AM  
10:16AM  
10:13AM  
07:36AM  
03:32AM  
Apr-02-20 10:36AM  
07:57AM  
Apr-01-20 10:46PM  
11:40AM  
Mar-31-20 12:32PM  
Mar-30-20 06:06PM  
11:47AM  
09:39AM  
Mar-29-20 03:27AM  
Mar-27-20 06:45PM  
12:48PM  
10:21AM  
Mar-26-20 04:24PM  
01:16PM  
02:49AM  
Mar-25-20 06:00AM  
Mar-24-20 09:57AM  
08:20AM  
Mar-23-20 10:15AM  
Mar-19-20 10:03AM  
07:37AM  
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. Its Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, established, and cardiovascular, renal and metabolism medicine products. The company's Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has collaboration agreements with Pear Therapeutics; Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Cancer Institute; Science 37; Bill & Melinda Gates Foundation; Amgen; University of California, Berkeley; Bristol-Myers Squibb; Drugs for Neglected Diseases initiative (DNDi); TScan Therapeutics; and Dyno Therapeutics Inc. The company was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerNov 12Buy12.00250,0003,000,0003,543,067Nov 12 04:15 PM